mRNA-2752

Phase 2RNA therapy

Moderna

mRNA-2752 is one of 68 biologic programs targeting Pancreatic Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CarcinomaActive, not recruiting

Colorectal CarcinomaActive, not recruiting

Pancreatic CarcinomaPhase 2

Active, not recruiting

Colorectal CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

102 competitors in Colorectal Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

2 2

Sutent

Pfizer

Phase 3

1 3

Iressa

AstraZeneca

Phase 3

1 4

Avastin

BBio-Thera Solutions

Phase 3

5 5

Vectibix

Golytely

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

2 8

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

2 9

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

1 10

Camptosar

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intratumoral Injection1 trial

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Completed· Moderna logo

Moderna·Phase 1·NCT03739931·134 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for mRNA-2752. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mRNA-2752 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mRNA-2752. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moderna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 2[1]
Company: Moderna

mRNA-2752

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intratumoral Injection1 trial

References

Drug Info

Quick Facts

Related News